乳腺癌是世界上女性患病率最高的肿瘤之一,BRCA1/2基因是常见的突变位点。Talazoparib,作为靶向PARP抑制剂,BRCA1/2基因突变能有效控制乳腺癌的发生、发展,并发挥治疗作用。根据III期EMBRACE试验(NCT01945775临床试验)的结果,我们的分析显示,talazoparib组的无进展生存期显着延长,与常规疗法相比,应答标志物和患者报告的结局也有所改善。本研究旨在评估他唑帕尼治疗具有种系BRCA1/2突变和HER2阴性的晚期乳腺癌的成本效益。考虑中国和美国卫生服务的前景。研究结果对促进合理用药、提高医疗资源利用效率具有参考价值。为了更科学地评估他拉索帕尼的成本效益,并为临床医生提供化疗方案,本文基于EMBRACA临床试验(clinicalTrails.govNo.,NCT01945775)来模拟他拉索帕利组和标准治疗组乳腺癌患者的生存事件。从III期EMBRACA临床试验中提取乳腺癌患者在治疗期间的状态转变概率和临床数据。治疗过程中产生的成本数据来自当地医院定价,其他参考文献,和专家咨询。本文使用美元计算治疗费用和增量成本效果比。健康结果以质量调整寿命年(QALYs)表示。此外,结果以质量调整寿命年(QALYs)衡量,和增量成本效益比,通过确定性和概率敏感性分析评估了其稳健性。本文建立了单项敏感性分析的马尔可夫模型。结果表明,中美使用他拉索帕利作为新的治疗策略的经济效益均高于其他药物,而且性价比很高。与对照组相比,Talazoparib治疗组在中国的增量成本为2484.48美元/QALY,增量QALY为1.5。然而,塔拉索帕利在美国占据主导地位,节省10,223.43美元的成本,并将QALY增加1.5。BRCA1/2突变晚期乳腺癌患者应用他唑帕尼组的临床治疗效果优于标准治疗组,无进展生存期显著延长。从中国和美国的医疗卫生服务来看,在治疗BRCA1/2突变型晚期乳腺癌患者方面,他拉索帕尼组比标准治疗组更经济.
Breast cancer is one of the tumors with the highest prevalence rate among women in the world, and its BRCA1/2 gene is a common mutation site. Talazoparib, as a targeted PARP inhibitor, can effectively control the occurrence and development of breast cancer with BRCA1/2 gene mutation, and play a therapeutic role. Based on the findings from the Phase III EMBRACE trial (NCT01945775 clinical trial), our analysis reveals that the talazoparib group demonstrated a significant extension in progression-free survival, along with improved response markers and patient-reported outcomes when compared to conventional therapies. This study aims to assess the cost-effectiveness of talazoparib for treating advanced breast cancer with germline BRCA1/2 mutations and HER2 negativity, considering the perspectives of health services in
China and the United States. The results obtained will serve as a valuable reference for promoting rational drug utilization and enhancing medical resource efficiency. To evaluate the cost-effectiveness of Talazoparib more scientifically and provide clinicians with chemotherapy options, this paper developed a Markov model based on the EMBRACA clinical trial (clinical Trails.gov No., NCT01945775) to simulate the survival events of breast cancer patients in the Talazoparib group and the standard treatment group. The state transition probability and clinical data of breast cancer patients during treatment were extracted from the phase III EMBRACA clinical trial. The cost data generated during the treatment process comes from local hospital pricing, other references, and expert consultation. This article uses US dollars to calculate the treatment cost and incremental cost-effectiveness ratio. Health outcomes are expressed in Quality Adjusted Life Years (QALYs). In addition, Outcomes were measured in quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio, which robustness was evaluated by deterministic and probabilistic sensitivity analyses. This article establishes a Markov model for single-item sensitivity analysis. The results show that the economic benefits of using Talazoparib as a new treatment strategy in both
China and the United States are higher than other drugs, and it is cost-effective. Compared to the control group, the incremental cost incurred by the Talazoparib treatment group in
China was $2484.48/QALY, with an incremental QALY of 1.5. However, Talazoparib in the United States holds a dominant position, saving costs of $10,223.43 and increasing QALYs by 1.5. The clinical treatment effect of Talazoparib group in BRCA1/2 mutant advanced breast cancer patients is better than that of the standard treatment group, and the progression free survival period is significantly prolonged. From the perspective of medical and health services in
China and the United States, the Talazoparib group is more economical than the standard treatment group in treating patients with BRCA1/2 mutant advanced breast cancer.